Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹356 Cr revenue.
COGS 56.9%, employees 5.3%.
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹356 Cr +6.3% | ₹335 Cr -11.5% | ₹379 Cr -5.3% | ₹400 Cr +4.9% | ₹381 Cr -13.0% | ₹438 Cr -10.7% | ₹491 Cr |
| Other Income | ₹42 Cr -32.0% | ₹62 Cr +6.1% | ₹58 Cr +75.1% | ₹33 Cr +0.3% | ₹33 Cr -8.4% | ₹36 Cr -53.8% | ₹78 Cr |
| Total Income | ₹398 Cr +0.4% | ₹397 Cr -9.2% | ₹437 Cr +0.9% | ₹433 Cr +4.5% | ₹414 Cr -12.6% | ₹474 Cr -16.6% | ₹569 Cr |
| COGS | ₹203 Cr +1.5% | ₹200 Cr -0.9% | ₹202 Cr +13.2% | ₹178 Cr +21.5% | ₹147 Cr -19.6% | ₹182 Cr -8.2% | ₹199 Cr |
| ₹268 Cr -2.2% | ₹274 Cr -14.8% | ₹321 Cr -17.0% | ₹387 Cr +3.4% | ₹374 Cr -16.0% | ₹446 Cr -7.7% | ₹483 Cr | |
| Profit Before Tax | ₹130 Cr +6.2% | ₹123 Cr +6.5% | ₹115 Cr ↑ Recovery | (₹4 Cr) ↓ Decline | ₹40 Cr +39.8% | ₹29 Cr -66.6% | ₹86 Cr |
| ₹30 Cr -21.6% | ₹38 Cr +213.2% | ₹12 Cr ↑ Recovery | (₹0.10 Cr) ↓ Decline | ₹19 Cr +3.1% | ₹19 Cr -45.4% | ₹34 Cr | |
| Net Profit | ₹101 Cr +18.4% | ₹85 Cr -17.6% | ₹103 Cr ↑ Recovery | (₹4 Cr) ↓ Decline | ₹21 Cr +107.3% | ₹10 Cr -80.5% | ₹52 Cr |
| Other Comprehensive Income | ₹0.97 Cr -19.8% | ₹1 Cr -61.1% | ₹3 Cr -62.0% | ₹8 Cr ↑ Recovery | (₹6 Cr) +69.1% | (₹20 Cr) ↓ Decline | ₹2 Cr |
| EPS | ₹40.87 | ₹34.50 | ₹41.86 | (₹1.51) | ₹8.46 | ₹4.08 | ₹20.97 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</...
Intimation of Newspaper Advertisement by Novartis India Limited (''the Company'')- Completion of e-mailing of Notice of Postal Ballot to the Members of the Company.
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve The Audited Financial Results .... Novartis...
Intimation of meeting of Board of Directors of Novartis India Limited("the Company") and Closure of Trading Window.
Intimation is hereby given that an order for demand was received on March 27, 2026, under Section 156 of the Income Tax Act, 1961. Further, an Order in the same regard has been received .... Intimatio...
This is to inform that Ms. Gowree Gokhale (DIN: 09351661) has been appointed as an Additional Director (designated as non-executive and Independent Director) w.e.f. April 01, 2026, for .... This is to...
Outcome of the meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 to inter-alia approve the completion of second tenure .... Outcome o...
Outcome of the meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 to inter-alia approve the appointment of Ms. Gowree Gokhale .... Out...
Outcome of the meeting of Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 inter-alia to approve the appointment of Ms. Gowree Gokhale .... Outcome...
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer to the public shareholders of Novartis India Ltd ("Target Company").
Axis Capital Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Novartis India Ltd under Regulation 3(1) .... Axis Capi...
Receipt of Public Announcement in relation to open offer from Axis Capital Limited (Manager to the Open Offer).
Disclosure under Regulation 30 of SEBI LODR Regulations.
Clarification regarding incorrect financial figures of Novartis India Limited for Q3 2025-26 reported in Free Press Journal article dated January 28, 2026. The article has now been taken down.
Intimation of newspaper advertisement by Novartis India Limited (''the Company'') regarding the publication of Unaudited Financial Results of the Company for the quarter ended December 31, 2025.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.